Response to Khandaker et al. Letter

Abstract

Back to table of contents Previous article Next article Communications and UpdatesFull AccessResponse to Khandaker et al. LetterLily N.L. Ho, M.B.CH.B.Lily N.L. HoHong Kong, ChinaSearch for more papers by this author, M.B.CH.B.Published Online:1 Sep 2010https://doi.org/10.1176/appi.ajp.2010.10030429rAboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Dr. Khandaker et al. mention that the development of manic symptoms in the patient, which occurred after oseltamivir use, may have been a red herring in the causation. This would be difficult to conclude, since she experienced only mild upper respiratory symptoms and fever for 1 day and the fever subsided before the start of oseltamivir and onset of manic symptoms. However, she and her parents could note that there was a marked change in her personality, with elated mood, after taking oseltamivir. A previous case series showed that neuropsychiatric adverse events after oseltamivir use may start on the first day of treatment (1). The close temporal relationship between the onset of manic symptoms and the use of oseltamivir in our patient, with relatively mild upper respiratory symptoms and fever that subsided before the onset of mania, suggests that oseltamivir-induced mania was a more likely diagnosis.Regarding the genetic difference, it has been suggested that a nonsynonymous single nucleotide polymorphism in human cytosolic sialidase is more prevalent in Asian populations. This polymorphism affects the activity of sialidase, which may cause neuropsychiatric adverse events in patients receiving oseltamivir (2). This may account for the observation that the majority of cases were reported in Japan.Both oseltamivir and influenza have been reported to be associated with the development of neuropsychiatric events (3–5). Moreover, fatal neuropsychiatric adverse reactions after oseltamivir use have been reported (1). The aim of our case report was to encourage vigilant monitoring of the mental state of patients after using oseltamivir until we have a better understanding about the properties of this drug.Hong Kong, Chinaaccepted for publication in April 2010.The author's disclosures accompany the original letter.